Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Biogen (NASDAQ:BIIB) stock traded flat as the company reports better than expected Q4 2024 financials, but its 2025 outlook ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Biogen shares fell, after the biotechnology company forecast lower-than-expected revenue and profit for this year, saying multiple-sclerosis drug sales will decline further and will only be partially ...

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

Biogen posted higher-than-expected revenue in its fourth quarter with sales from various products contributing to the top-line. The biotechnology pioneer on Wednesday said it logged net income of $266 ...

Total revenue is expected to decline by a mid-single digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis ...

Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as further declines in MS product revenue are expected to be partially offset by higher revenue from product ...